Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

1,726 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1990 1
1991 11
1992 27
1993 37
1994 38
1995 69
1996 46
1997 40
1998 49
1999 51
2000 64
2001 51
2002 66
2003 64
2004 76
2005 74
2006 81
2007 84
2008 62
2009 61
2010 104
2011 101
2012 89
2013 121
2014 92
2015 95
2016 88
2017 78
2018 67
2019 23
Text availability
Article attribute
Article type
Publication date

Search Results

1,726 results
Results by year
Filters applied: . Clear all
Page 1
Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems
Goldstuck ND. Expert Rev Med Devices 2017 - Review. PMID 28675069
Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. ...
Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. ...
Non-contraceptive benefits of intrauterine levonorgestrel administration: why not?
Sabbioni L, et al. Gynecol Endocrinol 2017 - Review. PMID 28586290
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. ...This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontraceptive benefits of intrauterine levonorgestrel in routinary practice. ...
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. ...This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontrac
Levonorgestrel-releasing intra-uterine systems as female contraceptives.
Grandi G, et al. Expert Opin Pharmacother 2018 - Review. PMID 29637798
INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. ...
INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. ...
Contraception and Breastfeeding
Pieh Holder KL. Clin Obstet Gynecol 2015 - Review. PMID 26457854
Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K, et al. Eur J Obstet Gynecol Reprod Biol 2017 - Clinical Trial. PMID 27930941
OBJECTIVE: To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use. ...
OBJECTIVE: To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use. ...
Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
McNicholas C, et al. Obstet Gynecol 2015 - Clinical Trial. PMID 25730221 Free PMC article.
Food and Drug Administration (FDA)-approved duration of 3 and 5 years, respectively. METHODS: Women willing to continue using their implant or 52-mg levonorgestrel IUD beyond the FDA-approved duration were followed prospectively for contraceptive effectiveness. ...Among 263 levonorgestrel IUD users, 197.7 women-years of follow-up have been completed. One pregnancy was confirmed, for a failure rate of 0.51 (95% CI 0.01-2.82) per 100 women-years. ...
Food and Drug Administration (FDA)-approved duration of 3 and 5 years, respectively. METHODS: Women willing to continue using their implant or 52-mg levonorgestrel IUD beyond the FDA-approved duration were followed prospectively for contraceptive effectiveness. ...Among 263 levonorg
Comparison of the levonorgestrel-releasing intrauterine system, hysterectomy, and endometrial ablation for heavy menstrual bleeding in a decision analysis model.
Louie M, et al. Int J Gynaecol Obstet 2017 - Review. PMID 28796898
OBJECTIVES: To provide comparative estimates of clinical outcomes after placement of levonorgestrel-releasing intrauterine system (LNG-IUS), ablation, or hysterectomy for AUB. ...CONCLUSIONS: Levonorgestrel-releasing intrauterine system and hysterectomy outperformed endometrial ablation for treatment of AUB....
OBJECTIVES: To provide comparative estimates of clinical outcomes after placement of levonorgestrel-releasing intrauterine system (LNG-IUS), ablation, or hysterectomy for AUB. ...CONCLUSIONS: Levonorgestrel-releasing intrauterine system and hysterectomy outperformed endometrial ablatio …
Practice Bulletin No. 152: Emergency Contraception
[No authors listed] Obstet Gynecol 2015 - Review. PMID 26287787
Food and Drug Administration (FDA) approved the first dedicated product for emergency contraception in 1998. Since then, several new products have been introduced. Methods of emergency contraception include oral administration of combined estrogen-progestin, progestin only, or selective progesterone receptor modulators and insertion of a copper intrauterine device (IUD). ...
Food and Drug Administration (FDA) approved the first dedicated product for emergency contraception in 1998. Since then, several new products have been introduced. Methods of emergency contraception include oral administration of combined estrogen-progestin, progestin only, or selectiv …
Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
Patseadou M and Michala L. Arch Gynecol Obstet 2017 - Review. PMID 27928678
PURPOSE: The levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective method of contraception, while also providing various non-contraceptive benefits. ...
PURPOSE: The levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective method of contraception, while also providing various non-contraceptive benefits. ...
Pregnancy outcomes with an IUD in situ: a systematic review
Brahmi D, et al. Contraception 2012 - Review. PMID 22067777 Free Books and Documents.
METHODS: We searched MEDLINE, POPLINE, EMBASE and LILACS databases from inception through April 2011 for peer-reviewed articles containing evidence related to pregnancy outcomes among women who conceived while using copper (Cu) and levonorgestrel-releasing (LNG) IUDs. ...
METHODS: We searched MEDLINE, POPLINE, EMBASE and LILACS databases from inception through April 2011 for peer-reviewed articles containing evidence related to pregnancy outcomes among women who conceived while using copper (Cu) and levonorgestrel-releasing (LNG) IUDs. ...
1,726 results
Jump to page
Feedback